Cavernomas enter the chart in three costumes. The incidental one, found on an MRI for headaches, that mostly needs to be explained rather than treated. The seizure one — a first convulsion, a rim of old blood in the temporal lobe. And the frightening one: a young patient with a pontine bleed, double vision, and a lesion the size of a fingertip sitting where nothing spare exists. One name, three very different conversations — priced apart by two variables: has it bled, and where does it live?2

What it is, and how MRI makes the diagnosis

A cerebral cavernous malformation (cavernoma, CCM) is a cluster of dilated, thin-walled vascular caverns with no intervening brain — a low-flow lesion that leaks and thromboses in small cycles rather than shunting like the high-flow tangle in the AVM chapter. Because flow is slow, catheter angiography is typically normal — this is the classic "angiographically occult" lesion — and the diagnosis is an MRI one: a reticulated popcorn core of blood products in varied ages, ringed by hemosiderin, with susceptibility sequences (the same SWI that finds microbleeds) lighting up lesions T2 misses.1 A neighboring developmental venous anomaly is common; it is the region's normal venous drainage wearing an unusual costume, and it is not resected.

One lesion or many? Solitary cavernomas (often DVA-associated) are usually sporadic. Multiple lesions — or a cavernoma with the right family story — point to the autosomal-dominant familial syndromes (KRIT1/CCM1, CCM2, PDCD10/CCM3), in which new lesions form over a lifetime; that changes genetic counseling and the imaging cadence, and it is a young-patient context worth flagging in the same breath as the rest of the young-stroke zebra list.1

The numbers that decide everything

The individual-patient meta-analysis of untreated cavernomas is the anchor: over five years, hemorrhage risk ran from roughly 4% for a non-brainstem cavernoma that had never bled, through intermediate figures for brainstem-unbled and hemispheric-bled lesions, to approximately 30% for a brainstem cavernoma presenting with hemorrhage — with rebleeding risk highest early and declining after the first years.2 Two clinical translations. First, the incidental cortical popcorn deserves a calm visit: its yearly number is small. Second, the once-bled brainstem lesion deserves a neurosurgical conversation at a center that sees these — not because surgery is automatic, but because the natural history is no longer benign.

"Cavernoma" without a location and a bleeding history is a word, not a prognosis.

Cavernoma bleeds are usually smaller and less devastating than arterial hemorrhages — brainstem excepted, where millimeters are eloquent — and the deficits often accumulate stepwise with each event, which is exactly why recurrent hemorrhage drives the surgical calculus.

Management, by scenario

  • Incidental lesion: education, a baseline susceptibility MRI, and follow-up imaging for change or symptoms — guidelines endorse conservative management as the default.1 No activity prohibition list accompanies it.
  • Seizure presentation: treat as lesional epilepsy — an antiseizure medication after a first seizure is generally warranted (drug-choice logic shared with the post-stroke epilepsy chapter). For epilepsy that proves medically refractory and maps to the cavernoma, resection has excellent seizure-freedom rates and is one of the two classic surgical indications.1
  • Symptomatic hemorrhage: acute care per hemorrhage pathway, then a risk conversation anchored to the numbers above. Surgery is favored for accessible lesions with recurrent symptomatic hemorrhage; brainstem lesions demand the most experienced hands and usually more than one event before resection wins the ledger. Radiosurgery is the contested consolation option for surgically inaccessible, repeatedly hemorrhaging lesions.
  • Familial disease: genetic counseling, screening discussion for relatives, and susceptibility MRI surveillance — with the honesty that we follow lesions, not treat the genome, at present.
  • Antithrombotics: the reflex "no blood thinners with a cavernoma" is not supported — observational cohorts and the pooled analyses have associated antithrombotic use with, if anything, no increase in hemorrhage. An indicated antiplatelet or anticoagulant (framework: antithrombotic selection) is generally not vetoed by an incidental cavernoma — individualized, as ever, for the once-bled brainstem lesion.1

The bottom line

Read the popcorn on SWI, then ask the two pricing questions: bled before, and where. The incidental hemispheric cavernoma gets a number small enough to live comfortably beside, a baseline scan, and no prohibitions. The seizure lesion gets epilepsy care, with resection held for refractory cases. The hemorrhagic brainstem lesion gets a real surgical conversation at an experienced center, timed by recurrence rather than reflex. Leave the DVA alone, don't reflexively strip indicated antithrombotics, and flag the multi-lesion patient for the familial workup. Common lesion, uncommon operations — in that order.